This is my wide angle view. Idronoxil is a plant based compound, delivered so as to give a sustained plasma level that evolution hasn't experienced. Ok, good but not that unusual. Now add that idronoxil is multiphasic, nudging many pathways for & against. It's necessary to take the good and bad here, but I like it as it indicates it's a core cellular influencer and might be targeted via dosage. The dosage rate is especially critical for multiphasic compounds and I've reason to believe we're nudging into the still tolerable, but more importantly optimal efficacy rates in our trials.
Re sepsis, that upside didn't exist a year ago, and now it exists with or without Covid. The timing of this latest patent application is very interesting imo.I'll also eat humble pie if I'm wrong, no problem. Comes with investing and making the call.
NOX Price at posting:
71.0¢ Sentiment: Hold Disclosure: Held
